DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Name: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
License: Public Domain

ImmunoVaccine Technologies, Inc. (IMV Inc.)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

relapsed diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 238102
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.